Katrine Bosley is an experienced biotech entrepreneur. Before joining Editas, a Cambridge startup aiming to translate genome-editing technology into human therapeutics, she was the Entrepreneur-in-Residence at the Broad Institute, a biomedical and genomic research center founded by MIT and Harvard. Prior to that, she was the CEO of Avila Therapeutics (acquired by Celgene). She served as vice president for business development at Adnexus Therapeutics and then for strategic operations after Adnexus was acquired by Bristol-Myers Squibb. Earlier, Bosley held several positions at Biogen in business development, commercial operations, and portfolio strategy and was part of the healthcare team at the venture firm Highland Capital Partners. She is a graduate of Cornell University. In addition to her role at Editas, Bosley currently serves as chairman of the board of Genocea Biosciences and is a board member of Galapagos NV and Scholar Rock, LLC. She is also a review committee member for the Translation Fund of the Wellcome Trust. Twitter: @ksbosley